cell

(redirected from myeloid cell)
Also found in: Dictionary, Thesaurus, Medical, Financial, Encyclopedia.
Related to myeloid cell: lymphoid cell

cell

(Enemy combatants), noun enemy group, exxremist group, rebel organization, saboteurs, subversives, unnerground extremists
Associated concepts: enemy combatants, justice courts, miliiary tribunals, Patriotic Act, prison cells, sleeper cell, terrorist cell

cell

(jail), noun cage, cella, chamber, compartment, confined room, confinement, cubicle, cubiculum, enclosed cage, incarceration, jailhouse, penitentiary, pound, prison, prison house, small cavity, small room, solitary abode
See also: chamber, jail, penitentiary, prison

CELL. A small room in a prison. See Dungeon.

References in periodicals archive ?
The heme enzyme myeloperoxidase (MPO), which is synthesized and secreted by neutrophils, monocytes, and other myeloid cells, is an important source of oxidants.
As the predominant infiltrating cell type in response to kidney injuries, myeloid cells play a pivotal role in the development of renal fibrosis.
Chronic myelogenous leukemia (CML) is a clonal disorder of myeloid cell production in the bone marrow.
To our knowledge, this is the first reported expression of total and free PSA in neoplastic myeloid cells obtained from different and well-established leukemic cell lines and detected by a commercial method.
lymphoid precursors and in some immature myeloid cells in the bone marrow.
Additionally, induction of myeloid cell differentiation following ex vivo treatment of patient blood samples with SY-1425 was significantly correlated with a positive biomarker test result.
Diabetic patients have many activated myeloid cells that could be causing disease symptoms.
When Pang purified the HSCs and grew them in laboratory dishes, she found that HSCs from older people were less able to differentiate into B lymphocytes and more likely to become myeloid cells.
The team deduced this after making close study of the methylation patterns in genomic regions containing genes known from other research to be expressed specifically in lymphoid cells, but not in myeloid cells, or vice versa.
Today the company's immuno-oncology portfolio includes novel checkpoint inhibitors, chimeric antigen receptor T-cell (CART) technology, myeloid cell targeting agents, the T cell stimulating factor IL-15, STING agonists that enhance immune recognition of cancers, and adenosine receptor antagonists and TGF-beta blocking antibodies that overcome immunosuppression in the tumor microenvironment.
With four candidates currently in clinical trials and five more agents expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating the body's immune system to combat cancers that includes novel checkpoint inhibitors, chimeric antigen receptor T-cell (CART) technology, myeloid cell targeting agents, and STING agonists.
The finding provides genetic insight into the high incidence of lymphoid leukemias in younger patients, as well as brings to light the fact that adult leukemias generally involve the myeloid cell lineages.